Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain

1. Balañá, C.
2. Vaz, M.A.
3. Lopez, D.
4. De La Peñas, R.
5. García-Bueno, J.M.
6. Molina-Garrido, M.J.
7. Sepúlveda, J.M.
8. Cano, J.M.
9. Bugés, C.
10. Sanz, S.M.
11. Arranz, J.L.
12. Perez-Segura, P.
13. Rodriguez, A.
14. Martin, J.M.
15. Benavides, M.
16. Gil, M.